Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 27, 2026, 8:55 pm
Author: Getaka|Social: XLinkedIn

Orchid Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 27, 2026, 8:55 pm

Market Cap 3,134 Cr.
Current Price 620
Intrinsic Value₹2,828.30
High / Low 1,005/604
Stock P/E121
Book Value 251
Dividend Yield0.00 %
ROCE8.07 %
ROE8.21 %
Face Value 10.0
PEG Ratio3.10

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Orchid Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Orchid Pharma Ltd 3,134 Cr. 620 1,005/604121 2510.00 %8.07 %8.21 % 10.0
RPG Life Sciences Ltd 3,097 Cr. 1,874 2,725/1,77229.5 3351.07 %32.8 %25.5 % 8.00
Advanced Enzyme Technologies Ltd 3,355 Cr. 300 367/25823.3 1331.73 %13.1 %9.54 % 2.00
Aarti Drugs Limited 3,358 Cr. 367 575/31218.1 1470.54 %13.5 %13.0 % 10.0
Gujarat Themis Biosyn Ltd 3,359 Cr. 308 479/20870.3 24.30.22 %27.3 %21.7 % 1.00
Industry Average20,545.80 Cr1,097.9755.88201.210.37%16.35%15.16%6.10

All Competitor Stocks of Orchid Pharma Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 165.25159.76209.90182.92198.76220.59217.10244.41222.70217.34237.48172.93193.52
Expenses 147.43146.10170.22160.78175.46185.21188.19211.92192.36190.97209.49158.75194.99
Operating Profit 17.8213.6639.6822.1423.3035.3828.9132.4930.3426.3727.9914.18-1.47
OPM % 10.78%8.55%18.90%12.10%11.72%16.04%13.32%13.29%13.62%12.13%11.79%8.20%-0.76%
Other Income 5.848.9334.171.898.367.6213.367.577.528.493.9011.4510.77
Interest 9.227.687.485.553.803.543.473.503.333.803.923.263.73
Depreciation 17.768.187.217.717.849.278.428.448.638.618.878.658.90
Profit before tax -3.326.7359.1610.7720.0230.1930.3828.1225.9022.4519.1013.72-3.33
Tax % 0.00%0.00%0.00%0.00%0.00%0.00%-10.27%-0.53%0.00%0.00%-0.21%0.00%0.00%
Net Profit -5.397.5959.149.4019.8029.4332.9629.3527.2420.7822.2914.91-5.72
EPS in Rs -1.321.8614.491.853.905.806.505.795.374.104.392.94-1.13

Last Updated: December 29, 2025, 6:04 pm

Below is a detailed analysis of the quarterly data for Orchid Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Sales, as of Sep 2025, the value is 193.52 Cr.. The value appears strong and on an upward trend. It has increased from 172.93 Cr. (Jun 2025) to 193.52 Cr., marking an increase of 20.59 Cr..
  • For Expenses, as of Sep 2025, the value is 194.99 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 158.75 Cr. (Jun 2025) to 194.99 Cr., marking an increase of 36.24 Cr..
  • For Operating Profit, as of Sep 2025, the value is -1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 14.18 Cr. (Jun 2025) to -1.47 Cr., marking a decrease of 15.65 Cr..
  • For OPM %, as of Sep 2025, the value is -0.76%. The value appears to be declining and may need further review. It has decreased from 8.20% (Jun 2025) to -0.76%, marking a decrease of 8.96%.
  • For Other Income, as of Sep 2025, the value is 10.77 Cr.. The value appears to be declining and may need further review. It has decreased from 11.45 Cr. (Jun 2025) to 10.77 Cr., marking a decrease of 0.68 Cr..
  • For Interest, as of Sep 2025, the value is 3.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.26 Cr. (Jun 2025) to 3.73 Cr., marking an increase of 0.47 Cr..
  • For Depreciation, as of Sep 2025, the value is 8.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.65 Cr. (Jun 2025) to 8.90 Cr., marking an increase of 0.25 Cr..
  • For Profit before tax, as of Sep 2025, the value is -3.33 Cr.. The value appears to be declining and may need further review. It has decreased from 13.72 Cr. (Jun 2025) to -3.33 Cr., marking a decrease of 17.05 Cr..
  • For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
  • For Net Profit, as of Sep 2025, the value is -5.72 Cr.. The value appears to be declining and may need further review. It has decreased from 14.91 Cr. (Jun 2025) to -5.72 Cr., marking a decrease of 20.63 Cr..
  • For EPS in Rs, as of Sep 2025, the value is -1.13. The value appears to be declining and may need further review. It has decreased from 2.94 (Jun 2025) to -1.13, marking a decrease of 4.07.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 6:46 am

MetricSep 2013n n 18mMar 2015n n 18mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,9481,747873797683600484450560666819922811
Expenses 1,8371,429703794659612515421505581708804769
Operating Profit 110317171324-12-3129558411111842
OPM % 6%18%20%0%4%-2%-6%7%10%13%14%13%5%
Other Income 92156-28-592021824156752312725
Interest 52353729434731076523333171514
Depreciation 2523251451411331301181098755333535
Profit before tax -573-389-296-544-39969-131-117248929617
Tax % -2%-49%-6%-9%-12%0%0%0%0%0%-3%-0%
Net Profit -560-197-279-495-35369-131-117-2469210019
EPS in Rs -79.21-23.06-31.37-55.69-39.657.80-32.11-28.55-0.4811.3518.1719.653.71
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-77.42%28.69%119.55%-289.86%10.69%98.29%2400.00%100.00%8.70%
Change in YoY Net Profit Growth (%)0.00%106.11%90.86%-409.40%300.54%87.60%2301.71%-2300.00%-91.30%

Orchid Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-6%
5 Years:14%
3 Years:18%
TTM:-3%
Compounded Profit Growth
10 Years:9%
5 Years:23%
3 Years:249%
TTM:-24%
Stock Price CAGR
10 Years:30%
5 Years:%
3 Years:33%
1 Year:-51%
Return on Equity
10 Years:%
5 Years:2%
3 Years:7%
Last Year:8%

Last Updated: September 5, 2025, 11:55 am

Balance Sheet

Last Updated: December 4, 2025, 1:45 am

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 70858989898941414141515151
Reserves 310244-40-556-881-7937256126076481,1191,2171,223
Borrowings 3,2043,2113,2153,1063,2023,230566453268331135175282
Other Liabilities 1,067521598616715551128132195205249246167
Total Liabilities 4,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,5541,6881,722
Fixed Assets 2,5841,7951,6371,4971,3861,256858670584573620633631
CWIP 36028228028827227826710463181120
Investments 1111100154544465049
Other Assets 1,7061,9841,9441,4701,4671,542576544472561857925922
Total Assets 4,6514,0613,8623,2563,1253,0771,4601,2371,1111,2251,5541,6881,722

Below is a detailed analysis of the balance sheet data for Orchid Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 51.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 51.00 Cr..
  • For Reserves, as of Sep 2025, the value is 1,223.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,217.00 Cr. (Mar 2025) to 1,223.00 Cr., marking an increase of 6.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 282.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 175.00 Cr. (Mar 2025) to 282.00 Cr., marking an increase of 107.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 167.00 Cr.. The value appears to be improving (decreasing). It has decreased from 246.00 Cr. (Mar 2025) to 167.00 Cr., marking a decrease of 79.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 1,722.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 631.00 Cr.. The value appears to be declining and may need further review. It has decreased from 633.00 Cr. (Mar 2025) to 631.00 Cr., marking a decrease of 2.00 Cr..
  • For CWIP, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 120.00 Cr., marking an increase of 39.00 Cr..
  • For Investments, as of Sep 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2025) to 49.00 Cr., marking a decrease of 1.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 922.00 Cr.. The value appears to be declining and may need further review. It has decreased from 925.00 Cr. (Mar 2025) to 922.00 Cr., marking a decrease of 3.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 1,722.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,688.00 Cr. (Mar 2025) to 1,722.00 Cr., marking an increase of 34.00 Cr..

Notably, the Reserves (1,223.00 Cr.) exceed the Borrowings (282.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 168-3692124019128124921812619
Cash from Investing Activity + -9861,334-1-176-284516767113-31-312-27
Cash from Financing Activity + 664-597-286-46533-0-250-165-2173116725
Net Cash Flow -153367-76-2401557-2-74-1118-1918

Free Cash Flow

MonthMar 2015n n 18mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2013n n 18m
Free Cash Flow317.00168.000.0021.00-15.00-597.00-424.00-213.00-247.00-24.00-57.00110.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthSep 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 3454130756473511101111188796
Inventory Days 187118220196202214254244201217199219
Days Payable 220146341402374381182176195165173149
Cash Conversion Cycle -0269-130-108-94123179117170113166
Working Capital Days -399-49-168-500-876-1,1581663029754118135
ROCE %-3%1%1%-4%-4%-5%-6%-5%-2%5%9%8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 89.96%72.40%72.40%69.84%69.84%69.84%69.84%69.84%69.84%69.84%69.84%69.84%
FIIs 0.81%8.58%8.08%4.14%1.96%1.42%1.94%2.53%2.69%1.39%1.56%1.17%
DIIs 2.62%13.48%12.46%14.51%17.73%18.93%18.30%19.00%20.10%19.43%19.04%19.38%
Public 6.60%5.54%7.05%11.52%10.47%9.82%9.94%8.63%7.37%9.34%9.57%9.61%
No. of Shareholders 29,52329,13229,19736,93136,72034,69536,36334,15834,30339,82738,15535,709

Shareholding Pattern Chart

No. of Shareholders

Orchid Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund 3,465,947 0.88 242.31,534,9192025-12-07 17:25:17125.81%
Invesco India Contra Fund 990,763 0.35 69.26N/AN/AN/A
Kotak Multi Asset Allocation Fund 942,962 0.54 65.92689,0172026-02-21 15:51:0336.86%
UTI Value Fund 787,231 0.56 55.04745,2302026-02-23 01:48:215.64%
Invesco India Smallcap Fund 455,183 0.35 31.82N/AN/AN/A
Kotak Special Opportunities Fund 427,811 2.1 29.91N/AN/AN/A
Bandhan Small Cap Fund 310,553 0.11 21.71294,2012026-01-26 08:21:045.56%
UTI Small Cap Fund 283,362 0.44 19.81445,0002025-12-08 01:35:25-36.32%
Kotak Consumption Fund 266,000 1.13 18.6N/AN/AN/A
Kotak Multicap Fund 264,308 0.08 18.48114,3082026-01-25 05:51:32131.22%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 19.6519.0611.35-0.48-28.55
Diluted EPS (Rs.) 19.6519.0611.35-0.48-28.55
Cash EPS (Rs.) 25.6925.3025.3021.71-1.87
Book Value[Excl.RevalReserv]/Share (Rs.) 249.86230.58168.72158.61159.96
Book Value[Incl.RevalReserv]/Share (Rs.) 249.86230.58168.72158.61159.96
Revenue From Operations / Share (Rs.) 181.77161.55163.14137.09110.26
PBDIT / Share (Rs.) 28.5227.9125.2515.2215.93
PBIT / Share (Rs.) 21.7121.3511.82-6.10-10.76
PBT / Share (Rs.) 18.8418.1313.54-13.94-23.34
Net Profit / Share (Rs.) 18.8818.7411.880.38-28.55
NP After MI And SOA / Share (Rs.) 19.6518.1711.35-0.47-28.55
PBDIT Margin (%) 15.6917.2715.4711.1014.44
PBIT Margin (%) 11.9413.217.24-4.44-9.75
PBT Margin (%) 10.3611.228.29-10.16-21.16
Net Profit Margin (%) 10.3811.607.270.28-25.89
NP After MI And SOA Margin (%) 10.8011.246.95-0.34-25.89
Return on Networth / Equity (%) 7.867.886.72-0.30-17.84
Return on Capital Employeed (%) 7.858.375.65-2.86-4.00
Return On Assets (%) 5.905.933.78-0.17-9.41
Long Term Debt / Equity (X) 0.100.100.210.320.65
Total Debt / Equity (X) 0.130.110.480.410.65
Asset Turnover Ratio (%) 0.560.580.570.470.30
Current Ratio (X) 2.833.041.351.873.87
Quick Ratio (X) 1.682.030.731.152.79
Inventory Turnover Ratio (X) 3.122.142.022.091.60
Interest Coverage Ratio (X) 9.958.653.201.941.27
Interest Coverage Ratio (Post Tax) (X) 7.596.811.50-0.77-0.85
Enterprise Value (Cr.) 3934.975169.071869.701420.3010472.28
EV / Net Operating Revenue (X) 4.276.312.812.5423.27
EV / EBITDA (X) 27.2036.5218.1422.86161.10
MarketCap / Net Operating Revenue (X) 4.276.472.362.0722.36
Price / BV (X) 3.114.532.281.7915.41
Price / Net Operating Revenue (X) 4.276.472.362.0722.36
EarningsYield 0.020.010.020.00-0.01

After reviewing the key financial ratios for Orchid Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 19.06 (Mar 24) to 19.65, marking an increase of 0.59.
  • For Cash EPS (Rs.), as of Mar 25, the value is 25.69. This value is within the healthy range. It has increased from 25.30 (Mar 24) to 25.69, marking an increase of 0.39.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 249.86. It has increased from 230.58 (Mar 24) to 249.86, marking an increase of 19.28.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 181.77. It has increased from 161.55 (Mar 24) to 181.77, marking an increase of 20.22.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 28.52. This value is within the healthy range. It has increased from 27.91 (Mar 24) to 28.52, marking an increase of 0.61.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 21.71. This value is within the healthy range. It has increased from 21.35 (Mar 24) to 21.71, marking an increase of 0.36.
  • For PBT / Share (Rs.), as of Mar 25, the value is 18.84. This value is within the healthy range. It has increased from 18.13 (Mar 24) to 18.84, marking an increase of 0.71.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 18.88. This value is within the healthy range. It has increased from 18.74 (Mar 24) to 18.88, marking an increase of 0.14.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.65. This value is within the healthy range. It has increased from 18.17 (Mar 24) to 19.65, marking an increase of 1.48.
  • For PBDIT Margin (%), as of Mar 25, the value is 15.69. This value is within the healthy range. It has decreased from 17.27 (Mar 24) to 15.69, marking a decrease of 1.58.
  • For PBIT Margin (%), as of Mar 25, the value is 11.94. This value is within the healthy range. It has decreased from 13.21 (Mar 24) to 11.94, marking a decrease of 1.27.
  • For PBT Margin (%), as of Mar 25, the value is 10.36. This value is within the healthy range. It has decreased from 11.22 (Mar 24) to 10.36, marking a decrease of 0.86.
  • For Net Profit Margin (%), as of Mar 25, the value is 10.38. This value exceeds the healthy maximum of 10. It has decreased from 11.60 (Mar 24) to 10.38, marking a decrease of 1.22.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 11.24 (Mar 24) to 10.80, marking a decrease of 0.44.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 7.86. This value is below the healthy minimum of 15. It has decreased from 7.88 (Mar 24) to 7.86, marking a decrease of 0.02.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 7.85. This value is below the healthy minimum of 10. It has decreased from 8.37 (Mar 24) to 7.85, marking a decrease of 0.52.
  • For Return On Assets (%), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 5.93 (Mar 24) to 5.90, marking a decrease of 0.03.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.10.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.13. This value is within the healthy range. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.56. It has decreased from 0.58 (Mar 24) to 0.56, marking a decrease of 0.02.
  • For Current Ratio (X), as of Mar 25, the value is 2.83. This value is within the healthy range. It has decreased from 3.04 (Mar 24) to 2.83, marking a decrease of 0.21.
  • For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.03 (Mar 24) to 1.68, marking a decrease of 0.35.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.12. This value is below the healthy minimum of 4. It has increased from 2.14 (Mar 24) to 3.12, marking an increase of 0.98.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 9.95. This value is within the healthy range. It has increased from 8.65 (Mar 24) to 9.95, marking an increase of 1.30.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.59. This value is within the healthy range. It has increased from 6.81 (Mar 24) to 7.59, marking an increase of 0.78.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 3,934.97. It has decreased from 5,169.07 (Mar 24) to 3,934.97, marking a decrease of 1,234.10.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.31 (Mar 24) to 4.27, marking a decrease of 2.04.
  • For EV / EBITDA (X), as of Mar 25, the value is 27.20. This value exceeds the healthy maximum of 15. It has decreased from 36.52 (Mar 24) to 27.20, marking a decrease of 9.32.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
  • For Price / BV (X), as of Mar 25, the value is 3.11. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.11, marking a decrease of 1.42.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.27. This value exceeds the healthy maximum of 3. It has decreased from 6.47 (Mar 24) to 4.27, marking a decrease of 2.20.
  • For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Orchid Pharma Ltd as of February 28, 2026 is: ₹2,034.66

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 28, 2026, Orchid Pharma Ltd is Undervalued by 228.17% compared to the current share price ₹620.00

Intrinsic Value of Orchid Pharma Ltd as of February 28, 2026 is: ₹2,828.30

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 28, 2026, Orchid Pharma Ltd is Undervalued by 356.18% compared to the current share price ₹620.00

Last 5 Year EPS CAGR: 39.01%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a low average Working Capital Days of -93.42, which is a positive sign.
  1. The stock has a low average ROCE of -0.42%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 47.58, which may not be favorable.
  3. The company has higher borrowings (1,644.46) compared to reserves (341.15), which may suggest financial risk.
  4. The company has not shown consistent growth in sales (589.77) and profit (-163.46).

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Orchid Pharma Ltd:
    1. Net Profit Margin: 10.38%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 7.85% (Industry Average ROCE: 16.35%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 7.86% (Industry Average ROE: 15.16%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 7.59
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.68
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 121 (Industry average Stock P/E: 55.88)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.13
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Orchid Pharma Ltd. is a Public Limited Listed company incorporated on 01/07/1992 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24222TN1992PLC022994 and registration number is 022994. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 921.93 Cr. and Equity Capital is Rs. 50.72 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Alathur, Chengalpattu Tamil Nadu 600110Contact not found
Management
NamePosition Held
Mr. Ram Gopal AgarwalChairman & Non-Exe.Director
Mr. Manish DhanukaManaging Director
Mr. Mridul DhanukaWhole Time Director
Mr. Arjun DhanukaNon Executive Director
Mrs. Tanu SinglaIndependent Woman Director
Dr. Dharam VirIndependent Director
Dr. Manoj Kumar GoyalIndependent Director
Ms. Shubha SinghIndependent Woman Director

FAQ

What is the intrinsic value of Orchid Pharma Ltd?

Orchid Pharma Ltd's intrinsic value (as of 27 February 2026) is ₹2828.30 which is 356.18% higher the current market price of ₹620.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,134 Cr. market cap, FY2025-2026 high/low of ₹1,005/604, reserves of ₹1,223 Cr, and liabilities of ₹1,722 Cr.

What is the Market Cap of Orchid Pharma Ltd?

The Market Cap of Orchid Pharma Ltd is 3,134 Cr..

What is the current Stock Price of Orchid Pharma Ltd as on 27 February 2026?

The current stock price of Orchid Pharma Ltd as on 27 February 2026 is ₹620.

What is the High / Low of Orchid Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Orchid Pharma Ltd stocks is ₹1,005/604.

What is the Stock P/E of Orchid Pharma Ltd?

The Stock P/E of Orchid Pharma Ltd is 121.

What is the Book Value of Orchid Pharma Ltd?

The Book Value of Orchid Pharma Ltd is 251.

What is the Dividend Yield of Orchid Pharma Ltd?

The Dividend Yield of Orchid Pharma Ltd is 0.00 %.

What is the ROCE of Orchid Pharma Ltd?

The ROCE of Orchid Pharma Ltd is 8.07 %.

What is the ROE of Orchid Pharma Ltd?

The ROE of Orchid Pharma Ltd is 8.21 %.

What is the Face Value of Orchid Pharma Ltd?

The Face Value of Orchid Pharma Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Orchid Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports